High-dose chemotherapy and peripheral blood stem cell infusion in patients with non-Hodgkin's lymphoma

Results of outpatient treatment in community cancer centers

C. H. Weaver, Lee Schwartzberg, B. Zhen, M. Mangum, R. Leff, K. Tauer, A. Rosenberg, K. Pendergrass, P. Kaywin, J. Hainsworth, F. A. Greco, W. H. West, C. D. Buckner

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

The outcomes for patients with non-Hodgkin's lymphoma (NHL) treated with high-dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) infusion by practicing oncologists in community cancer centers in the United States were determined. Eighty-three patients with NHL, who had failed conventional chemotherapy, underwent mobilization of PBSC with chemotherapy and a recombinant growth factor in an outpatient facility. At a median of 40 days (range 26-119) after mobilization chemotherapy all received carmustine (300 mg/m2 x 1), etoposide (150 mg/m2 twice a day x 4 days), cytarabine (100 mg/m2 twice a day x 4 days) and cyclophosphamide (35 mg/kg x 4 days) (BEAC) followed by infusion of unmanipulated PBSC in an outpatient facility. The probabilities of treatment-related mortality, relapse/progression, overall survival (OS) and event-free survival (EFS) at 3 years for all 83 patients were 0.07, 0.57, 0.49 and 0.38, respectively. The probabilities of relapse/progression, OS and EFS at 3 years for 28 patients who had failed primary induction chemotherapy were 0.55, 0.42 and 0.38, respectively. The probabilities of OS and EFS for 27 patients in untreated first relapse were 0.52 and 0.44, respectively, as compared to 0.56 and 0.32, respectively, for 18 patients who had reinduction attempts prior to receiving mobilization chemotherapg (P = 0.81 for OS and 0.99 for EFS). No significant risk factors for the outcomes of TRM, relapse/progression, OS or EFS could be identified. These data demonstrate that approximately 40 % of patients with NHL who have failed conventional chemotherapy become long-term disease-free survivors after mobilization chemotherapy, high-dose BEAC and PBSC infusion administered in an outpatient setting in community cancer centers, with the major cause of failure being relapse. Results obtained in this study are comparable to published data in similar patient populations receiving therapy as inpatients, suggesting that clinical trials involving well-tested HDC regimens can be carried out safely in this setting.

Original languageEnglish (US)
Pages (from-to)753-760
Number of pages8
JournalBone Marrow Transplantation
Volume20
Issue number9
DOIs
StatePublished - Nov 1 1997

Fingerprint

Non-Hodgkin's Lymphoma
Outpatients
Drug Therapy
Disease-Free Survival
Neoplasms
Recurrence
Survival
Therapeutics
Carmustine
Induction Chemotherapy
Peripheral Blood Stem Cells
Cytarabine
Etoposide
Cyclophosphamide
Survivors
Inpatients
Intercellular Signaling Peptides and Proteins
Clinical Trials
Mortality
Population

All Science Journal Classification (ASJC) codes

  • Hematology
  • Transplantation

Cite this

High-dose chemotherapy and peripheral blood stem cell infusion in patients with non-Hodgkin's lymphoma : Results of outpatient treatment in community cancer centers. / Weaver, C. H.; Schwartzberg, Lee; Zhen, B.; Mangum, M.; Leff, R.; Tauer, K.; Rosenberg, A.; Pendergrass, K.; Kaywin, P.; Hainsworth, J.; Greco, F. A.; West, W. H.; Buckner, C. D.

In: Bone Marrow Transplantation, Vol. 20, No. 9, 01.11.1997, p. 753-760.

Research output: Contribution to journalArticle

Weaver, CH, Schwartzberg, L, Zhen, B, Mangum, M, Leff, R, Tauer, K, Rosenberg, A, Pendergrass, K, Kaywin, P, Hainsworth, J, Greco, FA, West, WH & Buckner, CD 1997, 'High-dose chemotherapy and peripheral blood stem cell infusion in patients with non-Hodgkin's lymphoma: Results of outpatient treatment in community cancer centers', Bone Marrow Transplantation, vol. 20, no. 9, pp. 753-760. https://doi.org/10.1038/sj.bmt.1700975
Weaver, C. H. ; Schwartzberg, Lee ; Zhen, B. ; Mangum, M. ; Leff, R. ; Tauer, K. ; Rosenberg, A. ; Pendergrass, K. ; Kaywin, P. ; Hainsworth, J. ; Greco, F. A. ; West, W. H. ; Buckner, C. D. / High-dose chemotherapy and peripheral blood stem cell infusion in patients with non-Hodgkin's lymphoma : Results of outpatient treatment in community cancer centers. In: Bone Marrow Transplantation. 1997 ; Vol. 20, No. 9. pp. 753-760.
@article{bc531c57286f4eb58381643a13d9a84f,
title = "High-dose chemotherapy and peripheral blood stem cell infusion in patients with non-Hodgkin's lymphoma: Results of outpatient treatment in community cancer centers",
abstract = "The outcomes for patients with non-Hodgkin's lymphoma (NHL) treated with high-dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) infusion by practicing oncologists in community cancer centers in the United States were determined. Eighty-three patients with NHL, who had failed conventional chemotherapy, underwent mobilization of PBSC with chemotherapy and a recombinant growth factor in an outpatient facility. At a median of 40 days (range 26-119) after mobilization chemotherapy all received carmustine (300 mg/m2 x 1), etoposide (150 mg/m2 twice a day x 4 days), cytarabine (100 mg/m2 twice a day x 4 days) and cyclophosphamide (35 mg/kg x 4 days) (BEAC) followed by infusion of unmanipulated PBSC in an outpatient facility. The probabilities of treatment-related mortality, relapse/progression, overall survival (OS) and event-free survival (EFS) at 3 years for all 83 patients were 0.07, 0.57, 0.49 and 0.38, respectively. The probabilities of relapse/progression, OS and EFS at 3 years for 28 patients who had failed primary induction chemotherapy were 0.55, 0.42 and 0.38, respectively. The probabilities of OS and EFS for 27 patients in untreated first relapse were 0.52 and 0.44, respectively, as compared to 0.56 and 0.32, respectively, for 18 patients who had reinduction attempts prior to receiving mobilization chemotherapg (P = 0.81 for OS and 0.99 for EFS). No significant risk factors for the outcomes of TRM, relapse/progression, OS or EFS could be identified. These data demonstrate that approximately 40 {\%} of patients with NHL who have failed conventional chemotherapy become long-term disease-free survivors after mobilization chemotherapy, high-dose BEAC and PBSC infusion administered in an outpatient setting in community cancer centers, with the major cause of failure being relapse. Results obtained in this study are comparable to published data in similar patient populations receiving therapy as inpatients, suggesting that clinical trials involving well-tested HDC regimens can be carried out safely in this setting.",
author = "Weaver, {C. H.} and Lee Schwartzberg and B. Zhen and M. Mangum and R. Leff and K. Tauer and A. Rosenberg and K. Pendergrass and P. Kaywin and J. Hainsworth and Greco, {F. A.} and West, {W. H.} and Buckner, {C. D.}",
year = "1997",
month = "11",
day = "1",
doi = "10.1038/sj.bmt.1700975",
language = "English (US)",
volume = "20",
pages = "753--760",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - High-dose chemotherapy and peripheral blood stem cell infusion in patients with non-Hodgkin's lymphoma

T2 - Results of outpatient treatment in community cancer centers

AU - Weaver, C. H.

AU - Schwartzberg, Lee

AU - Zhen, B.

AU - Mangum, M.

AU - Leff, R.

AU - Tauer, K.

AU - Rosenberg, A.

AU - Pendergrass, K.

AU - Kaywin, P.

AU - Hainsworth, J.

AU - Greco, F. A.

AU - West, W. H.

AU - Buckner, C. D.

PY - 1997/11/1

Y1 - 1997/11/1

N2 - The outcomes for patients with non-Hodgkin's lymphoma (NHL) treated with high-dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) infusion by practicing oncologists in community cancer centers in the United States were determined. Eighty-three patients with NHL, who had failed conventional chemotherapy, underwent mobilization of PBSC with chemotherapy and a recombinant growth factor in an outpatient facility. At a median of 40 days (range 26-119) after mobilization chemotherapy all received carmustine (300 mg/m2 x 1), etoposide (150 mg/m2 twice a day x 4 days), cytarabine (100 mg/m2 twice a day x 4 days) and cyclophosphamide (35 mg/kg x 4 days) (BEAC) followed by infusion of unmanipulated PBSC in an outpatient facility. The probabilities of treatment-related mortality, relapse/progression, overall survival (OS) and event-free survival (EFS) at 3 years for all 83 patients were 0.07, 0.57, 0.49 and 0.38, respectively. The probabilities of relapse/progression, OS and EFS at 3 years for 28 patients who had failed primary induction chemotherapy were 0.55, 0.42 and 0.38, respectively. The probabilities of OS and EFS for 27 patients in untreated first relapse were 0.52 and 0.44, respectively, as compared to 0.56 and 0.32, respectively, for 18 patients who had reinduction attempts prior to receiving mobilization chemotherapg (P = 0.81 for OS and 0.99 for EFS). No significant risk factors for the outcomes of TRM, relapse/progression, OS or EFS could be identified. These data demonstrate that approximately 40 % of patients with NHL who have failed conventional chemotherapy become long-term disease-free survivors after mobilization chemotherapy, high-dose BEAC and PBSC infusion administered in an outpatient setting in community cancer centers, with the major cause of failure being relapse. Results obtained in this study are comparable to published data in similar patient populations receiving therapy as inpatients, suggesting that clinical trials involving well-tested HDC regimens can be carried out safely in this setting.

AB - The outcomes for patients with non-Hodgkin's lymphoma (NHL) treated with high-dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) infusion by practicing oncologists in community cancer centers in the United States were determined. Eighty-three patients with NHL, who had failed conventional chemotherapy, underwent mobilization of PBSC with chemotherapy and a recombinant growth factor in an outpatient facility. At a median of 40 days (range 26-119) after mobilization chemotherapy all received carmustine (300 mg/m2 x 1), etoposide (150 mg/m2 twice a day x 4 days), cytarabine (100 mg/m2 twice a day x 4 days) and cyclophosphamide (35 mg/kg x 4 days) (BEAC) followed by infusion of unmanipulated PBSC in an outpatient facility. The probabilities of treatment-related mortality, relapse/progression, overall survival (OS) and event-free survival (EFS) at 3 years for all 83 patients were 0.07, 0.57, 0.49 and 0.38, respectively. The probabilities of relapse/progression, OS and EFS at 3 years for 28 patients who had failed primary induction chemotherapy were 0.55, 0.42 and 0.38, respectively. The probabilities of OS and EFS for 27 patients in untreated first relapse were 0.52 and 0.44, respectively, as compared to 0.56 and 0.32, respectively, for 18 patients who had reinduction attempts prior to receiving mobilization chemotherapg (P = 0.81 for OS and 0.99 for EFS). No significant risk factors for the outcomes of TRM, relapse/progression, OS or EFS could be identified. These data demonstrate that approximately 40 % of patients with NHL who have failed conventional chemotherapy become long-term disease-free survivors after mobilization chemotherapy, high-dose BEAC and PBSC infusion administered in an outpatient setting in community cancer centers, with the major cause of failure being relapse. Results obtained in this study are comparable to published data in similar patient populations receiving therapy as inpatients, suggesting that clinical trials involving well-tested HDC regimens can be carried out safely in this setting.

UR - http://www.scopus.com/inward/record.url?scp=0030669937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030669937&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1700975

DO - 10.1038/sj.bmt.1700975

M3 - Article

VL - 20

SP - 753

EP - 760

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 9

ER -